Summary & Overview
HCPCS Level II J7658: Isoproterenol HCl Inhalation Solution, Concentrated
HCPCS Level II code J7658 represents isoproterenol hydrochloride inhalation solution, an FDA‑approved, non‑compounded concentrated product billed per milligram and administered via durable medical equipment. This code matters nationally as it captures billing for a niche inhaled bronchodilator used when specific therapeutic needs require isoproterenol delivered through a nebulizer system.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides an overview of payer coverage patterns, coding and billing benchmarks, and clinical context for use of inhaled isoproterenol through DME.
Readers will learn the clinical scope and service setting associated with J7658, typical billing considerations for DME‑administered inhalation drugs, and where to find benchmarks and policy updates relevant to payer coverage. The summary highlights national implications for coding consistency, procurement of concentrated inhalation products, and administrative documentation needed for billing. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J7658 describes isoproterenol hydrochloride inhalation solution, an FDA-approved, non-compounded final product supplied in a concentrated form and billed per milligram. The product is intended for administration via durable medical equipment (DME), indicating delivery through a nebulizer or other inhalation device rather than by direct nebulization in-clinic.
Service type: Inhalation drug administration via DME (nebulized bronchodilator therapy).
Typical site of service: Home or outpatient settings using durable medical equipment (DME), where patients receive inhaled medication through a prescribed nebulizer system.
Other fields: Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient with acute bronchospasm secondary to reactive airway disease or severe asthma is evaluated in an emergency department or outpatient pulmonary clinic. The clinician determines that inhaled bronchodilator therapy is required and elects to administer an FDA-approved, concentrated isoproterenol hydrochloride inhalation solution (J7658) via the patient’s durable medical equipment (DME) nebulizer. The workflow includes: initial assessment (vital signs, oxygen saturation), review of cardiac history due to isoproterenol’s beta-adrenergic effects, preparation of the concentrated non-compounded inhalation solution by pharmacy or qualified staff, delivery through the patient’s nebulizer attached to DME, monitoring for improvement in wheeze, dyspnea, and hemodynamic stability, and documentation of dosage in milligrams, route (inhalation), the DME device used, and any adverse effects. Typical sites of service include hospital outpatient departments, emergency departments, ambulatory infusion centers, and home health settings when the patient uses DME for inhalation therapy. Typical patients are adults or children with severe bronchospasm unresponsive to first-line inhaled beta-agonists or with specific indications for isoproterenol as determined by the treating clinician, often with close cardiac monitoring during administration.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (default) | Use when no special circumstances or modifier applicability exist for the drug administration. |